Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K.

Zhang T, Wang Q, Fredimoses M, Gao G, Wang K, Chen H, Wang T, Oi N, Zykova TA, Reddy K, Yao K, Ma W, Chang X, Lee MH, Rathore MG, Bode AM, Ashida H, Lippman SM, Dong Z.

Cancer Prev Res (Phila). 2018 Oct;11(10):607-620. doi: 10.1158/1940-6207.CAPR-18-0092. Epub 2018 Jul 6.

PMID:
29980517
2.

Two chalcones, 4-hydroxyderricin and xanthoangelol, stimulate GLUT4-dependent glucose uptake through the LKB1/AMP-activated protein kinase signaling pathway in 3T3-L1 adipocytes.

Ohta M, Fujinami A, Kobayashi N, Amano A, Ishigami A, Tokuda H, Suzuki N, Ito F, Mori T, Sawada M, Iwasa K, Kitawaki J, Ohnishi K, Tsujikawa M, Obayashi H.

Nutr Res. 2015 Jul;35(7):618-25. doi: 10.1016/j.nutres.2015.05.010. Epub 2015 May 30.

PMID:
26077869
3.

4-Hydroxyderricin and xanthoangelol from Ashitaba (Angelica keiskei) suppress differentiation of preadiopocytes to adipocytes via AMPK and MAPK pathways.

Zhang T, Sawada K, Yamamoto N, Ashida H.

Mol Nutr Food Res. 2013 Oct;57(10):1729-40. doi: 10.1002/mnfr.201300020. Epub 2013 May 16.

PMID:
23681764
4.

Bioassay-guided isolation and identification of anti-platelet-active compounds from the root of Ashitaba (Angelica keiskei Koidz.).

Son DJ, Park YO, Yu C, Lee SE, Park YH.

Nat Prod Res. 2014;28(24):2312-6. doi: 10.1080/14786419.2014.931389. Epub 2014 Jul 14.

PMID:
25019280
5.

Inhibitory effects of 4-hydroxyderricin and xanthoangelol on lipopolysaccharide-induced inflammatory responses in RAW264 macrophages.

Yasuda M, Kawabata K, Miyashita M, Okumura M, Yamamoto N, Takahashi M, Ashida H, Ohigashi H.

J Agric Food Chem. 2014 Jan 15;62(2):462-7. doi: 10.1021/jf404175t. Epub 2014 Jan 6.

PMID:
24369884
6.

Xanthoangelol and 4-Hydroxyderricin Are the Major Active Principles of the Inhibitory Activities against Monoamine Oxidases on Angelica keiskei K.

Kim JH, Son YK, Kim GH, Hwang KH.

Biomol Ther (Seoul). 2013 May 30;21(3):234-40. doi: 10.4062/biomolther.2012.100.

7.

Absorption and metabolism of 4-hydroxyderricin and xanthoangelol after oral administration of Angelica keiskei (Ashitaba) extract in mice.

Nakamura T, Tokushima T, Kawabata K, Yamamoto N, Miyamoto M, Ashida H.

Arch Biochem Biophys. 2012 May;521(1-2):71-6. doi: 10.1016/j.abb.2012.03.013. Epub 2012 Mar 20.

PMID:
22452965
8.

Anti-platelet effects of chalcones from Angelica keiskei Koidzumi (Ashitaba) in vivo.

Ohkura N, Ohnishi K, Taniguchi M, Nakayama A, Usuba Y, Fujita M, Fujii A, Ishibashi K, Baba K, Atsumi G.

Pharmazie. 2016 Nov 2;71(11):651-654. doi: 10.1691/ph.2016.6678.

PMID:
29441970
9.

Antitumor and antimetastatic actions of xanthoangelol and 4-hydroxyderricin isolated from Angelica keiskei roots through the inhibited activation and differentiation of M2 macrophages.

Sumiyoshi M, Taniguchi M, Baba K, Kimura Y.

Phytomedicine. 2015 Jul 15;22(7-8):759-67. doi: 10.1016/j.phymed.2015.05.005. Epub 2015 May 27.

PMID:
26141763
10.

PTP1B inhibitors from stems of Angelica keiskei (Ashitaba).

Li JL, Gao LX, Meng FW, Tang CL, Zhang RJ, Li JY, Luo C, Li J, Zhao WM.

Bioorg Med Chem Lett. 2015;25(10):2028-32. doi: 10.1016/j.bmcl.2015.04.003. Epub 2015 Apr 4.

PMID:
25891102
11.

Antidiabetic activities of chalcones isolated from a Japanese Herb, Angelica keiskei.

Enoki T, Ohnogi H, Nagamine K, Kudo Y, Sugiyama K, Tanabe M, Kobayashi E, Sagawa H, Kato I.

J Agric Food Chem. 2007 Jul 25;55(15):6013-7. Epub 2007 Jun 21.

PMID:
17583349
12.

The inhibitory effects of representative chalcones contained in Angelica keiskei on melanin biosynthesis in B16 melanoma cells.

Arung ET, Furuta S, Sugamoto K, Shimizu K, Ishikawa H, Matsushita Y, Kondo R.

Nat Prod Commun. 2012 Aug;7(8):1007-10.

PMID:
22978217
13.

Six new chalcones from Angelica keiskei inducing adiponectin production in 3T3-L1 adipocytes.

Ohnogi H, Kudo Y, Tahara K, Sugiyama K, Enoki T, Hayami S, Sagawa H, Tanimura Y, Aoi W, Naito Y, Kato I, Yoshikawa T.

Biosci Biotechnol Biochem. 2012;76(5):961-6. Epub 2012 May 7.

14.

Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.

Marsh Durban V, Deuker MM, Bosenberg MW, Phillips W, McMahon M.

J Clin Invest. 2013 Dec;123(12):5104-18. doi: 10.1172/JCI69619. Epub 2013 Nov 8.

15.

Separation of two major chalcones from Angelica keiskei by high-speed counter-current chromatography.

Kil YS, Nam JW, Lee J, Seo EK.

Arch Pharm Res. 2015 Aug;38(8):1506-11. doi: 10.1007/s12272-014-0530-2. Epub 2014 Dec 14.

PMID:
25502980
16.

Chalcones suppress fatty acid-induced lipid accumulation through a LKB1/AMPK signaling pathway in HepG2 cells.

Zhang T, Yamamoto N, Ashida H.

Food Funct. 2014 Jun;5(6):1134-41. doi: 10.1039/c3fo60694e. Epub 2014 Apr 11.

PMID:
24722377
17.

Melanoma: molecular pathogenesis and emerging target therapies (Review).

Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F, Malaponte G.

Int J Oncol. 2009 Jun;34(6):1481-9. Review.

PMID:
19424565
18.

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.

Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, de Braud F, Mortarini R, Anichini A.

Oncotarget. 2016 Jan 26;7(4):3947-65. doi: 10.18632/oncotarget.6600.

19.

Antibacterial activity of two chalcones, xanthoangelol and 4-hydroxyderricin, isolated from the root of Angelica keiskei KOIDZUMI.

Inamori Y, Baba K, Tsujibo H, Taniguchi M, Nakata K, Kozawa M.

Chem Pharm Bull (Tokyo). 1991 Jun;39(6):1604-5.

PMID:
1934181
20.

Ashitaba (Angelica keiskei) extract prevents adiposity in high-fat diet-fed C57BL/6 mice.

Zhang T, Yamashita Y, Yasuda M, Yamamoto N, Ashida H.

Food Funct. 2015 Jan;6(1):135-45. doi: 10.1039/c4fo00525b. Epub 2014 Nov 13.

PMID:
25406632

Supplemental Content

Support Center